Guillain-Barre syndrome: Guillain-BarrC) syndrome (GBS) is the term used to describe a spectrum of rare post-infectious neuropathies that usually occur in otherwise healthy patients. GBS is clinically heterogeneous and encompasses acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS; see these terms) and some other regional variants.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
665 |
4. Check minimum number of eventsNone |
665 |
5. Include endpointsNone |
665 |
6. Filter based on genotype QC (FinnGen only) |
598 |
Control definitions (FinnGen only)
- Control exclude
- G6_POLYNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G61
- Name in latin
- Syndroma Guillain-Barré
Similar endpoints
↥List of similar endpoints to
Guillain-Barre syndrome
based on the number of shared cases.
Similar with more cases:
- Polyneuropathies and other disorders of the peripheral nervous system
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4635 | 2063 | 2535 |
| Only index persons | 3894 | 1777 | 2117 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.06 | 0.07 |
| Only index persons | 0.07 | 0.07 | 0.08 |
| Median age at first event (years) | |||
| Whole population | 50.92 | 49.00 | 52.39 |
| Only index persons | 48.14 | 46.19 | 49.78 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 598 | 268 | 330 |
| Unadjusted period prevalence (%) | 0.13 | 0.10 | 0.15 |
| Median age at first event (years) | 53.00 | 48.87 | 56.36 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 620
- Matched controls
- 6200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G61.0
ICD-10 Finland
Guillain-Barré syndrome
4503599627370496.0
307.7
529
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
65.0
168.9
94
17
TAB00
NOMESCO Finland
Lumbar puncture
12.9
131.7
141
138
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
25.7
107.6
77
34
N99
ICPC
Neurological disease other
28.2
68.6
47
18
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
+∞
62.6
59
*
G61.9
ICD-10 Finland
Inflammatory polyneuropathy, unspecified
340.2
61.5
61
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.6
59.0
129
277
35401
ICD-8 Finland
Polyneuritis and polyradiculitis, Polyradicultitis Guillain-Barré
+∞
56.1
53
*
3570A
ICD-9 Finland
Inflammatory and toxic neuropathy, Acute infective polyneuritis
+∞
52.9
50
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
15.0
50.7
46
33
N28
ICPC
Limited function/disability (N)
15.2
48.9
44
31
R20.2
ICD-10 Finland
Paraesthesia of skin
5.4
47.4
104
222
6BA02, ,
NOMESCO Finland
224.8
41.4
42
*
N29
ICPC
Neurological sympt/complt other
10.1
35.4
41
43
R4120
NOMESCO Finland
Occupational therapy
4.7
34.4
88
212
ZX120
NOMESCO Finland
Intravenous
3.8
30.9
106
317
N03AX16
ATC
[U] pregabalin
2.9
30.5
198
871
N03AX12
ATC
[U] gabapentin; oral
3.1
30.1
155
599
WW400
NOMESCO Finland
Plasmaferesis
317.1
30.1
30
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.7
27.6
97
294
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
8.1
26.2
36
47
G62.8
ICD-10 Finland
Other specified polyneuropathies
97.6
25.9
28
*
AA1AD
NOMESCO Finland
CT of head and brain
2.5
25.2
235
1219
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.3
24.4
68
174
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
8.7
23.3
30
36
G35
ICD-10 Finland
Multiple sclerosis
8.7
20.3
26
31
G51.0
ICD-10 Finland
Bell palsy
6.0
20.0
36
63
G82.2
ICD-10 Finland
Paraplegia, unspecified
37.1
20.0
25
7
N94
ICPC
Peripheral neuritis/neuropathy
108.5
19.7
21
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.5
18.6
148
700
L28
ICPC
Limited function/disability (L)
2.4
17.4
140
664
R1250
NOMESCO Finland
Evaluation of functional capability
5.4
16.9
34
66
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.6
16.4
58
175
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
5.1
14.9
32
66
XF400
NOMESCO Finland
ECG with 12 standard connections
2.4
14.6
121
578
N18
ICPC
Paralysis/weakness
5.9
13.8
25
44
L04AX01
ATC
azathioprine; systemic
3.9
13.1
40
109
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.2
12.4
128
667
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.3
12.3
104
499
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.6
12.0
77
326
R4110
NOMESCO Finland
Physiotherapy
1.9
12.0
189
1147
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
66.2
11.6
13
*
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.8
11.4
35
96
R53
ICD-10 Finland
Malaise and fatigue
1.9
11.0
174
1053
TPH04
NOMESCO Finland
Cathetrisation of vein
1.9
10.8
153
892
N06AA09
ATC
amitriptyline; systemic
2.6
10.7
66
274
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
111.8
10.4
11
*
N02BF02
ATC
pregabalin; oral
2.8
10.4
53
199
XA402
NOMESCO Finland
ENMG
4.5
10.3
25
57
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
4.8
10.3
23
49
N06AX21
ATC
duloxetine; oral
2.3
10.3
86
409
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
13.4
10.2
17
13
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
3.8
10.0
30
81
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
3.5
9.7
33
97
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.6
9.7
58
237
H02AB07
ATC
prednisone; oral
2.2
9.6
91
456
Z3226
NOMESCO Finland
Physiotherapist
2.0
9.5
122
683
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
9.4
307
2271
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
+∞
9.4
9
*
C03CA01
ATC
furosemide; systemic
1.8
9.3
189
1227
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
37.3
9.0
11
*
H02AB06
ATC
prednisolone; systemic
1.7
9.0
296
2187
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.2
8.8
76
367
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.8
8.7
43
159
R4130
NOMESCO Finland
Speech therapy
3.9
8.6
25
66
GBB00
NOMESCO Finland
Tracheostomy
7.5
8.5
19
26
G63.0*A69.2
ICD-10 Finland
Polyneuropathy (in) Lyme disease
91.3
8.4
9
*
M48.0
ICD-10 Finland
Spinal stenosis
2.1
8.3
86
446
G82.5
ICD-10 Finland
Tetraplegia, unspecified
33.8
8.1
10
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.0
8.0
87
458
Z01.8
ICD-10 Finland
Other specified special examinations
1.8
8.0
144
896
ZXD05
NOMESCO Finland
Urgent procedure
1.7
8.0
188
1262
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.7
7.9
165
1072
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.7
7.7
170
1119
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.7
7.7
190
1290
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
4.6
7.7
18
40
M03BX01
ATC
baclofen; systemic
4.1
7.7
21
53
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.7
7.6
41
159
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
10.2
7.6
14
14
Z3231
NOMESCO Finland
Registered nurse
1.7
7.5
172
1143
G61
ICD-10 Finland
Inflammatory polyneuropathy
81.0
7.4
8
*
2AB04, ,
NOMESCO Finland
30.4
7.2
9
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.1
7.1
67
334
R60.9
ICD-10 Finland
Oedema, unspecified
2.6
7.1
41
165
A28
ICPC
Limited function/disability NOS
1.8
7.0
111
662
E11.4
ICD-10 Finland
Type 2 diabetes mellitus, with neurological complications
4.1
6.9
19
48
G63.2*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic polyneuropathy
40.5
6.8
8
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
2.9
6.7
32
116
109
Kela drug reimbursment
Multiple sclerosis
7.3
6.7
15
21
M54.1
ICD-10 Finland
Radiculopathy
3.0
6.7
30
105
T78.4
ICD-10 Finland
Allergy, unspecified
3.0
6.7
29
100
TQW11
NOMESCO Finland
Vacuum treatment of wound
4.1
6.7
18
45
N03AX09
ATC
lamotrigine; oral
2.6
6.6
37
146
M79.2
ICD-10 Finland
Neuralgia and neuritis, unspecified
3.7
6.5
20
55
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
3.7
6.5
20
55
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
3.3
6.5
24
75
NA7DM
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with 3 Tesla magnet
70.6
6.4
7
*
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
4.1
6.4
17
42
R20.8
ICD-10 Finland
Other and unspecified disturbances of skin sensation
6.7
6.4
15
23
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
2.5
6.3
39
162
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.1
6.2
14
20
G64
ICD-10 Finland
Other disorders of peripheral nervous system
27.0
6.2
8
*
5AB01, ,
NOMESCO Finland
27.0
6.2
8
*
N03AE01
ATC
clonazepam; systemic
2.5
6.2
39
164
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
7.8
6.1
13
17
A49.9
ICD-10 Finland
Bacterial infection, unspecified
1.9
6.1
74
405
N02BF01
ATC
gabapentin; oral
2.0
6.0
67
356
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
2.8
6.0
30
112
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
162
121
17.77
180.12
1.3
1.2
3.81
3.72
mmol/l
0.34
155
114
168
137
16.45
177.73
1.4
1.3
848.49
441.88
mg/l
11.61
163
130
115
50
28.01
163.10
1.1
1.1
—
—
—
0
0
142
123
14.68
143.71
1.4
1.3
9.36
15.95
e6/l
0.35
105
95
142
125
14.44
142.25
1.4
1.3
427.53
994.05
e6/l
0.27
112
100
87
44
22.84
115.24
1.3
1.1
76.10
43.99
mg/l
1.88
78
37
78
38
23.34
104.74
1.2
1.0
—
—
—
0
0
79
43
20.91
101.07
1.2
1.1
531.52
238.13
mg/l
4.46
71
38
168
354
6.14
79.93
2.8
2.4
21.45
17.20
au/ml
0.21
13
33
158
318
6.33
78.80
1.5
1.3
51.77
30.47
au/ml
—
6
24
63
36
19.37
78.46
1.4
1.1
0.67
0.50
ratio
2.19
38
24
58
30
21.23
75.48
1.1
1.0
1.24
1.16
u/l
0.16
28
14
65
49
14.70
70.05
1.1
1.4
—
—
—
0
0
50
23
23.56
68.19
1.2
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
51
27
20.49
65.54
1.1
1.1
—
—
—
0
0
38
20
20.18
48.72
1.2
1.3
—
—
—
0
0
155
458
4.18
47.21
2.7
2.3
10.32
10.96
g/l
0.90
142
427
240
1123
2.86
33.38
1.7
1.4
2.37
2.50
g/l
0.54
188
719
133
453
3.46
31.97
3.1
2.8
66.74
66.80
g/l
0.03
124
422
306
1664
2.66
31.14
2.8
2.1
685.51
279.71
u/l
0.40
291
1582
47
71
7.08
30.16
1.2
1.1
—
—
—
0
0
36
17
22.40
25.04
1.3
1.4
—
—
—
0
0
68
214
3.45
18.08
3.1
2.1
7.27
7.29
g/l
0.04
63
199
68
214
3.45
18.08
3.1
2.1
4.08
4.21
g/l
0.64
63
199
68
214
3.45
18.08
3.1
2.1
3.37
3.67
g/l
1.27
63
199
62
186
3.59
17.73
2.7
2.1
10.11
10.84
g/l
0.46
57
170
65
202
3.48
17.62
3.1
2.1
2.79
3.07
g/l
1.26
60
187
28
19
15.37
17.29
1.1
1.1
—
—
—
0
0
72
242
3.23
17.22
1.9
2.3
33.42
39.33
u/l
1.58
66
218
28
22
13.27
16.30
1.1
1.5
127.57
159.70
nmol/l
1.23
28
22
22
9
25.26
16.10
1.1
1.3
—
—
—
0
0
174
933
2.20
16.07
3.6
3.4
0.81
0.82
mmol/l
0.77
167
893
24
17
14.63
14.64
1.1
1.1
—
—
—
0
0
24
17
14.63
14.64
1.1
1.1
—
—
—
0
0
19
7
27.93
14.34
1.1
1.4
—
—
—
0
0
24
18
13.82
14.31
1.1
1.2
—
—
—
0
0
413
3106
1.99
14.22
13.2
9.8
4.08
4.13
e9/l
0.16
365
2708
58
194
3.20
13.95
2.6
2.3
0.38
1.18
g/l
1.18
53
173
23
17
14.00
13.82
1.1
1.1
—
—
—
0
0
18
7
26.41
13.43
1.3
1.1
—
—
—
0
0
24
22
11.30
13.11
1.0
1.0
—
—
—
0
0
22
17
13.37
13.00
1.1
1.0
—
—
—
0
0
334
2396
1.85
12.65
7.3
5.2
34.58
35.75
g/l
2.96
316
2258
16
5
32.78
12.62
1.1
1.4
—
—
—
0
0
25
48
5.39
12.58
1.1
1.1
0.12
2.22
nmol/l
—
5
6
15
5
30.68
11.69
1.1
1.6
—
—
—
0
0
137
750
2.06
11.58
7.3
6.1
1.02
1.03
mmol/l
0.17
129
700
236
1559
1.83
11.34
1.9
1.7
20.57
20.32
nmol/l
0.09
210
1327
435
3471
1.85
10.86
6.7
4.5
73.30
842.45
e6/l
—
10
58
408
3201
1.80
10.68
9.0
5.1
6.78
6.68
mmol/l
0.43
395
3041
322
2361
1.76
10.65
2.5
2.1
92.32
95.43
pmol/l
0.57
195
1281
145
846
1.93
10.10
1.8
1.7
1150.71
1155.06
nmol/l
0.02
119
653
100
521
2.10
9.53
7.1
7.0
9.29
9.94
mmol/l
0.38
94
500
37
120
3.22
9.37
6.1
6.2
1699.13
255.25
iu/ml
—
8
16
15
12
12.77
8.90
1.1
1.1
—
—
—
0
0
253
1805
1.68
8.71
5.0
3.4
28.03
102.47
e6/l
1.26
203
1382
348
2697
1.66
8.67
11.6
7.3
1.21
1.21
mmol/l
0.01
307
2359
204
1382
1.71
8.48
2.6
2.2
3.09
2.92
mg/l
0.42
166
1186
318
2420
1.64
8.42
11.1
6.5
1.20
1.21
mmol/l
0.62
301
2249
19
27
7.22
8.30
3.0
2.1
—
—
—
0
0
185
1226
1.73
8.30
2.0
1.7
1.64
1.23
mg/l
0.55
147
962
222
1550
1.67
8.18
4.7
3.2
0.27
0.48
e6/l
1.17
176
1130
186
1239
1.72
8.17
3.8
2.7
3.88
4.87
e6/l
1.09
176
1135
119
696
1.88
8.09
2.5
1.9
—
—
—
0
0
11
5
22.36
8.04
1.1
1.4
—
—
—
0
0
29
91
3.29
7.76
2.6
3.6
—
3498.38
—
0
8
39
146
2.78
7.72
1.2
1.3
—
—
—
0
0
23
62
3.81
7.69
1.2
1.9
—
—
—
0
0
147
935
1.75
7.54
2.5
1.9
—
—
—
0
0
304
2334
1.59
7.44
2.8
2.5
76.25
76.44
nmol/l
0.04
281
2117
11
7
15.96
7.25
1.2
1.1
—
—
—
0
0
50
224
2.34
6.88
1.5
2.0
3.73
6.54
iu/ml
0.78
12
59
14
17
8.40
6.85
1.3
1.1
125.33
82.87
nmol/l
—
9
11
49
218
2.35
6.85
1.3
1.2
5.12
2.18
u/ml
—
5
13
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
41
170
2.51
6.67
2.8
2.4
0.30
0.35
iu/ml
0.68
19
79
44
189
2.43
6.64
1.3
1.3
—
—
—
0
0
359
2915
1.55
6.54
7.6
6.9
11.37
11.78
umol/l
0.36
350
2804
354
2867
1.55
6.51
5.0
3.8
20.68
0.00
estimate
0.49
77
614
53
251
2.22
6.41
1.8
2.1
1.58
1.54
g/l
0.12
47
227
36
148
2.52
5.98
1.3
1.3
2.66
2.91
u/ml
—
7
19
36
148
2.52
5.98
1.3
1.3
2.28
5.63
u/ml
—
6
27
34
137
2.57
5.88
1.4
1.5
—
—
—
0
0
30
114
2.71
5.82
1.3
1.2
44.10
54.02
u/ml
—
5
16
353
2902
1.50
5.74
5.0
3.8
0.00
0.54
estimate
0.52
73
576
106
661
1.73
5.73
2.5
1.9
—
—
—
0
0
72
399
1.91
5.72
2.1
1.7
—
—
—
0
0
456
3966
1.57
5.63
5.7
4.3
13.91
11.72
mm/h
2.39
433
3704
346
2848
1.49
5.49
5.0
3.8
0.00
0.00
estimate
-0.00
75
603
89
538
1.76
5.36
2.5
2.0
325.16
385.69
nmol/l
2.36
81
510
466
4090
1.56
5.35
11.1
8.5
78.48
80.13
u/l
0.28
451
3908
40
182
2.28
5.34
4.9
4.0
39.20
55.58
mg/l
0.49
34
159
40
182
2.28
5.34
4.9
4.0
43.46
87.51
mg/l
0.72
34
158
315
2557
1.47
5.28
12.9
14.3
1.18
1.24
inr
1.62
265
2141
89
547
1.73
5.05
5.6
3.5
2.07
1.77
mmol/l
0.33
80
469
59
319
1.94
5.05
4.8
3.9
2.13
1.78
mmol/l
0.42
46
233
103
661
1.67
4.99
14.5
8.0
1.59
0.77
mmol/l
1.30
89
551
139
965
1.57
4.89
4.3
3.0
1.06
0.90
e6/l
0.29
80
508
308
2514
1.45
4.88
3.4
3.0
279.12
133.72
ug/l
0.89
285
2356
23
85
2.77
4.73
1.3
1.3
—
—
—
0
0
23
85
2.77
4.73
1.3
1.3
—
—
—
0
0
36
166
2.24
4.68
4.7
3.7
1.63
2.56
ratio
0.66
21
93
34
153
2.29
4.68
1.6
1.6
—
—
—
0
0
142
1002
1.54
4.63
1.4
1.3
42.56
33.30
iu/ml
0.25
38
306
37
175
2.19
4.54
1.6
1.5
0.26
0.12
iu/ml
—
7
31
13
27
4.89
4.52
1.1
1.0
1594.08
1480.41
miu/ml
0.13
13
27
132
928
1.54
4.36
2.7
2.5
12.14
13.30
umol/l
1.12
123
867
101
668
1.61
4.33
14.8
7.9
11.39
12.08
kpa
1.22
96
648
7
6
11.78
4.28
1.4
1.2
—
—
—
0
0
7
6
11.78
4.28
1.0
1.2
—
—
—
0
0
17
56
3.09
4.27
1.3
1.9
—
—
—
0
0
19
67
2.89
4.26
1.1
1.3
—
—
—
0
0
178
1340
1.46
4.20
3.5
2.5
—
—
—
0
0
33
155
2.19
4.13
1.6
1.6
—
—
—
0
0
123
862
1.53
4.10
2.6
2.5
2.31
2.29
g/l
0.12
117
803
27
117
2.37
4.07
1.5
1.5
—
—
—
0
0
8
10
8.09
4.07
1.0
1.0
—
—
—
0
0
114
794
1.53
3.91
13.0
7.0
104.09
104.33
mmol/l
0.24
114
794
39
202
1.99
3.81
1.8
1.7
—
—
—
0
0
56
327
1.78
3.81
20.5
9.7
15.63
15.87
%
0.28
56
315
126
903
1.50
3.77
4.6
3.1
3.63
1.76
e6/l
0.73
67
446
147
1087
1.46
3.76
1.9
1.7
446.21
20540971.59
pmol/l
0.77
121
925
113
793
1.52
3.74
2.6
2.6
22.00
23.60
%
0.67
106
747
82
537
1.61
3.66
2.6
2.4
0.21
0.21
g/l
0.03
72
512
23
98
2.40
3.61
1.5
1.6
—
—
—
0
0
25
111
2.30
3.59
1.3
1.5
—
—
—
0
0
31
151
2.11
3.58
1.6
1.3
—
—
—
0
0
7
10
7.06
3.37
1.0
1.0
—
—
—
0
0
410
3643
1.37
3.37
4.6
3.4
54.66
50.68
u/l
0.39
389
3472
14
48
2.96
3.32
1.9
3.5
—
—
—
0
0
144
1087
1.42
3.27
5.3
4.0
324.81
366.89
ng/l
0.08
118
841
29
144
2.06
3.21
1.3
1.1
—
—
—
0
0
218
1770
1.36
3.18
3.9
2.7
71.22
106.79
u/l
0.35
205
1669
32
167
1.97
3.10
1.4
1.3
—
—
—
0
0
159
1237
1.38
3.01
1.4
1.3
0.58
1.75
u/ml
2.35
36
350
93
658
1.49
2.95
3.3
2.9
10.37
8.38
umol/l
0.21
79
584
297
2549
1.32
2.90
3.8
2.8
—
—
estimate
—
0
0
33
179
1.89
2.88
1.3
1.4
—
—
—
0
0
203
1655
1.34
2.83
3.3
3.2
1673.00
1306.52
ng/l
0.41
175
1425
82
571
1.50
2.82
17.4
8.5
118.85
121.73
g/l
0.62
82
560
34
189
1.85
2.76
1.9
1.5
—
—
—
0
0
13
48
2.74
2.73
1.2
1.3
—
—
—
0
0
229
1908
1.32
2.73
3.7
3.3
32.73
33.62
u/l
0.12
213
1813
197
1612
1.33
2.65
5.4
3.8
0.00
0.01
estimate
0.96
72
562
27
141
1.96
2.64
1.7
1.7
—
—
—
0
0
12
41
2.96
2.63
1.3
1.2
—
—
—
0
0
7
15
4.71
2.60
3.4
1.9
—
—
—
0
0
19
87
2.22
2.59
1.2
1.1
6.31
17.79
iu/ml
—
8
19
27
142
1.94
2.59
1.4
1.1
—
—
—
0
0
5
7
7.19
2.55
1.0
1.0
88.00
94.43
%
—
5
7
218
1820
1.31
2.52
3.4
3.6
2.33
2.35
mmol/l
2.65
205
1657
11
37
3.01
2.50
1.0
1.6
—
—
—
0
0
11
37
3.01
2.50
1.0
1.6
—
—
—
0
0
78
552
1.47
2.49
4.6
3.1
—
—
—
0
0
75
527
1.48
2.48
3.6
2.6
59.78
32.91
u/l
0.54
67
448
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
7
16
4.41
2.48
1.0
1.1
127.86
128.50
%
—
7
16
53
346
1.58
2.45
2.0
1.7
—
—
—
0
0
175
1433
1.31
2.31
3.6
2.9
356.20
350.19
umol/l
0.28
155
1279
34
203
1.71
2.22
2.3
2.9
—
—
—
0
0
20
101
2.01
2.17
1.5
1.8
—
—
—
0
0
12
49
2.48
2.11
2.8
3.7
75.26
31.78
u/ml
—
5
16
22
117
1.91
2.08
2.0
1.6
—
—
—
0
0
78
572
1.42
2.08
2.7
2.4
12.84
13.51
nmol/l
0.33
72
521
15
69
2.20
2.06
1.6
1.6
—
—
—
0
0
20
104
1.95
2.02
1.8
1.5
157.49
156.63
au/ml
—
7
27
14
63
2.25
2.02
2.8
2.9
14.00
20.15
mg/l
—
6
28
361
3272
1.25
1.97
3.1
3.1
—
—
—
0
0
8
27
2.99
1.94
1.5
3.3
2297.75
900.67
u/ml
—
8
27
13
58
2.27
1.92
1.2
1.2
—
—
—
0
0
44
293
1.54
1.91
1.6
1.4
—
—
—
0
0
52
360
1.49
1.89
5.4
2.8
130.42
129.54
g/l
0.10
52
351
543
5190
1.37
1.85
27.9
16.1
22.11
24.38
mg/l
0.97
472
4313
21
115
1.86
1.85
1.8
1.5
—
—
—
0
0
49
341
1.47
1.75
1.2
1.2
140.46
137.84
u/ml
0.02
25
135
9
36
2.52
1.74
3.4
4.1
0.56
0.86
index
—
9
36
242
2123
1.23
1.72
5.0
3.8
34.28
61.83
ng/l
0.50
170
1519
11
49
2.27
1.64
1.2
1.2
—
—
—
0
0
33
214
1.57
1.63
1.9
1.9
—
—
—
0
0
61
449
1.40
1.63
2.2
2.4
8.35
7.76
ug/l
0.07
55
407
37
247
1.53
1.61
1.6
1.3
—
—
—
0
0
89
697
1.32
1.61
1.9
1.8
1.44
1.46
%
0.07
75
614
14
70
2.02
1.60
1.6
1.6
—
—
—
0
0
18
99
1.84
1.59
3.9
3.0
8.58
8.86
pmol/l
0.05
18
99
23
137
1.70
1.57
2.0
1.9
6.40
5.35
iu/l
—
8
49
51
366
1.43
1.57
11.7
6.1
25.41
24.43
mmol/l
1.14
51
350
115
940
1.27
1.52
1.3
1.3
6.22
12.28
u/ml
1.06
39
369
428
4006
1.22
1.51
4.3
4.1
14.64
14.73
pmol/l
0.38
393
3673
20
116
1.75
1.50
1.4
1.3
245.64
273.55
u/ml
0.21
14
58
81
639
1.31
1.41
5.4
4.9
32.02
31.72
%
0.07
54
431
10
46
2.19
1.40
1.2
1.2
—
—
—
0
0
503
4803
1.25
1.38
5.5
5.1
1.83
1.92
mu/l
1.27
472
4440
23
143
1.63
1.37
3.1
1.6
—
—
—
0
0
10
47
2.15
1.34
1.2
1.2
—
—
—
0
0
62
475
1.34
1.32
3.4
2.5
0.25
0.53
e6/l
0.70
56
458
243
2177
1.19
1.32
5.6
3.7
0.00
0.03
estimate
2.27
62
519
35
243
1.47
1.31
5.6
3.2
26.33
25.20
mmol/l
1.09
35
234
548
5295
1.30
1.30
32.2
19.0
3.97
3.98
mmol/l
0.38
536
5192
10
48
2.10
1.28
1.1
1.5
—
—
—
0
0
11
55
2.02
1.28
1.2
1.6
—
—
—
0
0
8
35
2.30
1.27
1.4
1.7
—
—
—
0
0
547
5288
1.29
1.26
31.5
18.9
139.41
139.68
mmol/l
1.84
538
5196
10
49
2.06
1.22
1.2
1.2
—
—
—
0
0
14
78
1.81
1.22
1.3
1.6
—
—
—
0
0
14
78
1.81
1.22
1.3
1.6
—
—
—
0
0
18
109
1.67
1.20
5.1
3.9
37.22
28.02
mg/l
—
10
82
14
79
1.79
1.17
1.3
1.6
—
—
—
0
0
14
80
1.77
1.13
1.4
1.6
—
—
—
0
0
23
151
1.54
1.13
3.2
3.4
4.00
1.76
index
0.90
12
93
7
30
2.35
1.12
1.0
1.5
—
—
—
0
0
7
30
2.35
1.12
1.0
1.5
—
—
—
0
0
7
30
2.35
1.12
1.4
1.7
—
—
—
0
0
14
81
1.75
1.09
1.4
1.6
—
—
—
0
0
14
81
1.75
1.09
1.4
1.6
—
—
—
0
0
8
41
1.96
1.09
1.4
1.6
—
—
—
0
0
7
32
2.20
1.08
1.1
1.1
—
—
—
0
0
7
33
2.13
1.06
1.4
1.7
—
—
—
0
0
205
1846
1.17
1.01
5.2
4.2
5.03
8.59
mg/mmol
1.64
134
1172
7
35
2.01
1.00
1.0
1.1
—
—
—
0
0
51
400
1.30
0.97
4.3
4.1
103.87
86.54
ng/l
0.56
46
354
10
54
1.87
0.97
1.3
1.7
—
—
—
0
0
10
54
1.87
0.97
1.3
1.7
—
—
—
0
0
10
54
1.87
0.97
1.2
1.2
—
—
—
0
0
10
54
1.87
0.97
1.3
1.7
—
—
—
0
0
213
1931
1.16
0.96
4.6
3.5
7.55
8.02
mmol/l
0.82
175
1633
6
27
2.23
0.93
1.0
3.3
0.50
1.56
%
—
6
27
6
27
2.23
0.93
1.5
1.6
—
—
—
0
0
146
1288
1.17
0.93
5.9
3.8
1.02
1.02
kg/l
0.18
106
854
520
5037
1.20
0.92
24.0
15.4
83.31
81.79
ml/min/173m2
0.87
494
4681
6
29
2.08
0.89
2.3
1.7
95.17
79.05
ng/l
—
6
29
13
79
1.66
0.88
1.0
1.2
1.40
4.79
u/ml
—
5
29
27
195
1.40
0.87
1.4
1.6
31.90
8.72
u/ml
—
5
46
18
120
1.51
0.86
15.3
6.5
105.39
105.08
mmol/l
0.11
18
110
18
120
1.51
0.86
15.3
6.5
10.28
11.42
mmol/l
1.21
18
110
31
231
1.36
0.84
1.3
1.4
38.11
24.63
iu/l
0.77
24
196
6
31
1.94
0.84
1.0
1.7
—
—
—
0
0
6
31
1.94
0.84
1.0
1.7
—
—
—
0
0
6
31
1.94
0.84
1.0
1.7
—
—
—
0
0
176
1589
1.15
0.83
5.0
3.2
0.00
0.06
estimate
0.63
58
499
15
97
1.56
0.82
1.5
1.5
—
—
—
0
0
6
33
1.83
0.79
1.0
1.4
86.17
83.12
umol/l
—
6
33
23
165
1.41
0.79
1.7
1.4
254.93
293.92
ug/g
0.39
14
95
10
59
1.71
0.76
1.6
1.2
0.82
1.43
nmol/l
—
10
53
5
24
2.09
0.74
3.8
3.2
35.40
36.44
umol/l
—
5
17
20
142
1.42
0.73
1.2
1.4
—
—
—
0
0
5
26
1.93
0.70
2.2
2.2
—
—
—
0
0
69
592
1.19
0.64
7.8
7.1
—
—
—
0
0
230
2148
1.11
0.62
6.0
5.5
2.17
2.80
ug/l
0.54
209
1949
8
49
1.64
0.62
1.1
1.1
—
—
—
0
0
5
30
1.67
0.61
1.8
1.8
—
—
—
0
0
5
30
1.67
0.61
1.8
1.8
—
—
—
0
0
8
50
1.61
0.61
1.1
1.1
—
—
—
0
0
17
122
1.40
0.60
1.4
1.5
—
—
—
0
0
8
52
1.55
0.59
1.1
1.0
—
—
—
0
0
6
35
1.72
0.58
1.5
1.7
—
—
—
0
0
561
5514
1.18
0.57
33.2
20.8
76.41
79.13
umol/l
1.71
555
5453
504
4919
1.13
0.56
7.3
6.4
40.09
39.33
mmol/mol
0.88
471
4642
11
73
1.52
0.56
1.4
1.5
0.56
25.58
nmol/l
0.49
11
68
76
667
1.16
0.55
1.8
1.5
—
—
—
0
0
17
125
1.37
0.54
1.5
1.5
0.82
0.95
ratio
0.90
12
82
17
125
1.37
0.54
1.5
1.5
1.10
1.11
ratio
0.01
12
82
32
262
1.23
0.49
10.7
4.7
1.75
1.58
%
0.49
32
249
450
4385
1.10
0.45
31.8
19.7
13.78
13.62
%
1.76
444
4348
5
31
1.62
0.43
1.0
1.5
3.40
2.35
u/field
—
5
21
5
31
1.62
0.43
1.0
1.7
—
—
—
0
0
48
416
1.17
0.43
1.5
1.4
—
—
—
0
0
5
32
1.57
0.42
2.2
1.5
—
—
—
0
0
480
4899
0.91
0.42
4.6
4.3
1.40
1.29
mmol/l
2.31
441
4553
65
579
1.14
0.41
2.6
2.1
—
—
—
0
0
555
5473
1.13
0.41
17.5
12.2
28.32
27.12
u/l
0.79
543
5347
0
17
0.00
0.40
0.0
1.3
—
0.71
—
0
12
114
1051
1.10
0.40
2.5
2.9
2.44
2.45
mmol/l
0.24
107
947
9
66
1.37
0.38
1.6
1.5
—
—
—
0
0
31
264
1.18
0.35
3.5
1.6
0.29
0.34
mg/l
0.21
16
118
181
1717
1.08
0.34
4.3
4.6
21.45
21.58
%
0.04
90
823
20
163
1.23
0.34
1.8
2.3
5114.29
6001.72
u/l
—
7
61
6
45
1.34
0.34
1.0
1.2
59.83
100.78
pmol/l
—
6
45
7
99
0.70
0.31
1.7
1.6
—
—
—
0
0
14
174
0.80
0.30
1.3
1.1
1.38
1.54
g/l
1.10
14
174
11
141
0.78
0.29
2.0
3.2
1.83
1.57
mmol/l
0.39
11
136
69
634
1.10
0.28
2.9
2.2
—
—
—
0
0
10
76
1.32
0.28
7.6
5.2
406.60
354.27
umol/l
—
10
69
11
85
1.30
0.28
1.1
1.5
—
—
—
0
0
52
572
0.90
0.27
3.0
4.7
644.45
26.48
ug/l
0.53
36
482
10
128
0.78
0.27
1.7
1.3
—
—
—
0
0
9
75
1.20
0.25
1.0
1.1
—
—
—
0
0
508
5142
0.93
0.25
5.4
5.0
1.38
1.43
mmol/l
2.16
467
4805
518
5238
0.93
0.24
6.0
5.8
2.63
2.70
mmol/l
0.93
477
4903
5
43
1.16
0.21
2.6
3.2
15.00
52.39
u/ml
—
5
43
6
48
1.25
0.20
1.0
1.4
2.01
2.94
ug/l
—
6
42
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
31
279
1.12
0.19
3.4
3.7
49.75
48.71
%
0.08
31
273
10
81
1.24
0.19
1.0
1.2
1.60
4.50
u/ml
—
5
40
23
258
0.89
0.18
1.0
1.0
—
—
—
0
0
10
83
1.21
0.15
1.0
1.1
2.01
1.51
g/l
—
10
76
16
181
0.88
0.14
1.3
1.1
1.02
0.90
g/l
0.51
16
181
512
5160
0.96
0.14
5.4
5.1
4.52
4.59
mmol/l
0.75
473
4848
568
5651
1.06
0.12
39.7
24.5
249.05
246.80
e9/l
0.34
557
5559
11
95
1.16
0.11
1.0
1.1
1.22
2.24
eliau/ml
—
5
35
568
5653
1.06
0.11
39.5
24.4
91.23
91.12
fl
0.21
561
5606
23
211
1.09
0.11
1.7
1.6
992.69
952.77
mu/l
0.09
17
179
568
5654
1.05
0.11
39.6
24.4
4.42
4.52
e12/l
3.77
553
5546
568
5654
1.05
0.11
41.2
24.9
39.83
40.60
%
2.78
561
5599
25
231
1.09
0.10
2.0
3.3
8.67
1087.58
u/ml
1.10
18
202
131
1276
1.03
0.10
3.6
3.2
0.73
0.76
ug/l
0.22
96
821
568
5656
1.05
0.10
39.9
24.6
133.18
136.33
g/l
4.63
561
5604
21
194
1.09
0.09
2.4
1.8
—
—
—
0
0
30
283
1.06
0.08
3.5
2.2
—
—
—
0
0
7
66
1.06
0.08
3.4
3.5
—
—
—
0
0
15
137
1.10
0.07
1.7
1.5
—
—
—
0
0
8
74
1.08
0.07
1.3
1.1
—
—
—
0
0
8
75
1.07
0.07
1.0
1.1
—
—
—
0
0
45
433
1.04
0.06
3.2
2.8
66.61
68.46
ml/min/173m2
0.12
18
201
56
576
0.97
0.05
1.8
2.1
3.83
3.54
ratio
0.69
45
456
11
101
1.09
0.04
1.3
1.1
0.16
1.72
u/ml
—
5
58
500
5015
0.98
0.03
5.6
5.1
6.08
5.95
mmol/l
0.99
452
4636
228
2266
1.01
0.02
2.1
2.0
1.44
1.37
mmol/l
0.68
184
1922
18
172
1.05
0.02
1.8
1.4
387.75
257.05
miu/ml
—
8
84
41
419
0.98
0.02
1.5
1.8
3.74
3.51
mmol/l
0.45
29
304
97
960
1.01
0.02
1.7
1.6
—
—
—
0
0
15
146
1.03
0.00
1.5
1.4
—
—
—
0
0
33
335
0.98
0.00
3.4
2.3
—
—
—
0
0
15
147
1.02
0.00
1.3
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
65
0.92
-0.00
1.2
1.1
—
—
—
0
0
8
79
1.01
-0.00
2.3
1.7
—
—
—
0
0
5
55
0.91
-0.00
1.0
1.1
79.40
96.88
%
—
5
50
0
9
0.00
-0.00
0.0
7.8
—
6.27
—
0
9
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.2
—
82.56
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_GUILBAR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_GUILBAR | 2.186 [1.81, 2.63] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.473 |
During the follow-up period (1.1.1998 — 31.12.2019), 256 out of 1332 females with G6_GUILBAR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_GUILBAR | 1.876 [1.59, 2.21] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 391 out of 1622 males with G6_GUILBAR died.
Mortality risk
Mortality risk for people of age
years, who have G6_GUILBAR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.24% | 0.382% |
| 5 | 1.313% | 1.977% |
| 10 | 3.35% | 4.535% |
| 15 | 6.366% | 8.683% |
| 20 | 11.367% | 14.611% |
Relationships between endpoints
↥Index endpoint: G6_GUILBAR – Guillain-Barre syndrome
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data